IL-17 cytokine family members have diverse biological functions, promoting protective
immunity against many pathogens but also driving inflammatory pathology during infection …

The vast interindividual clinical variability observed in any microbial infection—ranging from
silent infection to lethal disease—is increasingly being explained by human genetic and …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin
(IL)-17A and IL-17F. We assessed the efficacy and safety of bimekizumab in patients with …

Since the first Immune Checkpoint Inhibitor was developed, tumor immunotherapy has
entered a new era, and the response rate and survival rate of many cancers have also been …

Background Psoriasis is an immune‐mediated disease with either skin or joints
manifestations, or both, and it has a major impact on quality of life. Although there is …

In this 13th annual installment of the annual 'Antibodies to Watch'article series, we discuss
key events in commercial antibody therapeutics development that occurred in 2021 and …

Psoriasis is the result of uncontrolled keratinocyte proliferation, and its pathogenesis
involves the dysregulation of the immune system. The interplay among cytokines released …

Background Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-
17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the …

Importance Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high
burden for patients and limited existing therapeutic options. Objective To evaluate the …

Objectives Axial spondyloarthritis (axSpA) is a complex disease with diverse manifestations,
for which new treatment options are warranted. BE MOBILE 1 (non-radiographic (nr)-axSpA) …